Showing results (211-220 of 221) with videos related to

Sort By:
Pageof 23
Elife|February 15, 2017
Suppressor of cytokine signaling (SOCS)5 ameliorates influenza infection via inhibition of EGFR signalingLukasz Kedzierski, Michelle D Tate, Alan C Hsu, et al.
British Journal of Clinical Pharmacology|January 5, 2022
Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patientsFrank M P van Haren, Lex M van Loon, Anne Steins, et al.
Progress in Nuclear Magnetic Resonance Spectroscopy|December 6, 2025
Experience of how to build an MRI machine from scratchShaoying Huang, José Miguel Algarín, Joseba Alonso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based AnalysesTilak K Sundaresan, Lecia V Sequist, John V Heymach, et al.
Nature Communications|November 28, 2018
VDAC2 enables BAX to mediate apoptosis and limit tumor developmentHui San Chin, Mark X Li, Iris K L Tan, et al.
Journal of Neurointerventional Surgery|June 12, 2025
Multicenter evaluation of the safety and efficacy of varying doses of cangrelor used in acute cerebrovascular stenting in patients with acute ischemic strokeDevin N Holden, James Spencer Dingman, Lauren H Sutton, et al.
British Journal of Cancer|November 14, 2018
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancerJosé Robles-Zurita, Kathleen A Boyd, Andrew H Briggs, et al.
JCO Oncology Practice|March 6, 2025
Health-Related Quality of Life for Persons Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (AMC-A01)Thomas M Atkinson, Madhu Mazumdar, Grace Van Hyfte, et al.
The Lancet. Oncology|April 4, 2018
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trialTimothy J Iveson, Rachel S Kerr, Mark P Saunders, et al.
Health Technology Assessment (Winchester, England)|December 20, 2019
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCTTimothy Iveson, Kathleen A Boyd, Rachel S Kerr, et al.
Pageof 23